Guggenheim still thinks Oculis Holding is a good buy but has cut its price target to $40.

Nov 4, 2026, 11:39 AM ETOpinionRead the original at tradingview.com

Neutral

Oculis received mixed broker commentary: Guggenheim kept its Buy rating but cut its target by 11.1%. The report gives no new information about Oculis's business, so it does not change the company's outlook.

OCS · Oculis Holding AG

AI read · Neutral

The AI's read

This is one analyst's view, not a report of a change in Oculis's medicines, sales, or finances. Keeping the Buy rating supports the company, but the lower target points the other way. Neither side changes the company facts described here.

Get alerts for OCS

Follow Oculis Holding AG (OCS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for OCS

Free on the App Store and Google Play, or on the web.